Healthcare provider profile · identity verified

Lily Ruan

Nurse Practitioner · NEW YORK, NY · NPI 1306997291

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Eliquis	Apixaban	490	69
Amlodipine Besylate	Amlodipine Besylate	431	63
Atorvastatin Calcium	Atorvastatin Calcium	292	72
Metoprolol Tartrate	Metoprolol Tartrate	264	46
Pantoprazole Sodium	Pantoprazole Sodium	261	49
Famotidine	Famotidine	240	46
Gabapentin	Gabapentin	231	57
Furosemide	Furosemide	228	38
Levothyroxine Sodium	Levothyroxine Sodium	227	41
Losartan Potassium	Losartan Potassium	222	40
Tamsulosin Hcl	Tamsulosin Hcl	211	44
Citalopram Hbr	Citalopram Hydrobromide	199	26
Metoprolol Succinate	Metoprolol Succinate	181	33
Hydralazine Hcl	Hydralazine Hcl	168	26
Clopidogrel	Clopidogrel Bisulfate	151	24
Metformin Hcl	Metformin Hcl	149	15
Memantine Hcl	Memantine Hcl	142	19
Escitalopram Oxalate	Escitalopram Oxalate	134	20
Donepezil Hcl	Donepezil Hcl	117	21
Latanoprost	Latanoprost	111	27
Levetiracetam	Levetiracetam	95	15
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	89	15
Carvedilol	Carvedilol	89	17
Trazodone Hcl	Trazodone Hcl	87	14
Mirtazapine	Mirtazapine	85	18
Nifedipine Er	Nifedipine	85	15
Divalproex Sodium	Divalproex Sodium	82	13
Lisinopril	Lisinopril	80	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	79	14
Carbidopa-Levodopa	Carbidopa/Levodopa	69	11
Midodrine Hcl	Midodrine Hcl	67	11
Finasteride	Finasteride	65	12
Quetiapine Fumarate	Quetiapine Fumarate	62	suppressed
Simvastatin	Simvastatin	60	11
Labetalol Hcl	Labetalol Hcl	59	suppressed
Amantadine	Amantadine Hcl	55	suppressed
Alendronate Sodium	Alendronate Sodium	53	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	53	19
Olanzapine	Olanzapine	51	suppressed
Tradjenta	Linagliptin	50	suppressed
Potassium Chloride	Potassium Chloride	49	11
Risperidone	Risperidone	49	suppressed
Torsemide	Torsemide	49	suppressed
Duloxetine Hcl	Duloxetine Hcl	48	suppressed
Jardiance	Empagliflozin	48	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	47	suppressed
Januvia	Sitagliptin Phosphate	47	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	44	14
Omeprazole	Omeprazole	43	suppressed
Methenamine Hippurate	Methenamine Hippurate	41	suppressed
Metformin Hcl Er	Metformin Hcl	40	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	40	suppressed
Entresto	Sacubitril/Valsartan	39	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	39	suppressed
Atenolol	Atenolol	38	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	38	suppressed
Sertraline Hcl	Sertraline Hcl	37	suppressed
Santyl	Collagenase Clostridium Hist.	35	suppressed
Montelukast Sodium	Montelukast Sodium	34	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	33	suppressed
Silodosin	Silodosin	33	suppressed
Kapspargo Sprinkle	Metoprolol Succinate	31	suppressed
Lactulose	Lactulose	31	20
Baclofen	Baclofen	30	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	30	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	30	suppressed
Levocarnitine	Levocarnitine	30	suppressed
Pravastatin Sodium	Pravastatin Sodium	29	suppressed
Gemtesa	Vibegron	26	suppressed
Glipizide	Glipizide	25	suppressed
Allopurinol	Allopurinol	24	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	23	suppressed
Dutasteride	Dutasteride	23	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	22	suppressed
Admelog Solostar	Insulin Lispro	21	suppressed
Aripiprazole	Aripiprazole	21	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Enalapril Maleate	Enalapril Maleate	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	11
Hydroxyurea	Hydroxyurea	19	suppressed
Meclizine Hcl	Meclizine Hcl	19	suppressed
Digoxin	Digoxin	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Rasagiline Mesylate	Rasagiline Mesylate	18	suppressed
Renvela	Sevelamer Carbonate	18	suppressed
Linzess	Linaclotide	17	suppressed
Namzaric	Memantine Hcl/Donepezil Hcl	17	suppressed
Oxcarbazepine	Oxcarbazepine	17	suppressed
Vascepa	Icosapent Ethyl	17	suppressed
Amiodarone Hcl	Amiodarone Hcl	16	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	16	suppressed
Nateglinide	Nateglinide	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Albuterol Sulfate	Albuterol Sulfate	15	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	15	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	15	11
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Zenpep	Lipase/Protease/Amylase	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Bumetanide	Bumetanide	14	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	14	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	14	suppressed
Movantik	Naloxegol Oxalate	14	suppressed
Nystatin-Triamcinolone	Nystatin/Triamcinolone Acet	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Rhopressa	Netarsudil Mesylate	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Folic Acid	Folic Acid	13	suppressed
Gemfibrozil	Gemfibrozil	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Prednisone	Prednisone	13	suppressed
Abiraterone Acetate	Abiraterone Acetate	12	suppressed
Diltiazem 24hr Er (La)	Diltiazem Hcl	12	suppressed
Insulin Lispro Protamine Mix	Insulin Lispro Protamin/Lispro	12	suppressed
Methimazole	Methimazole	12	suppressed
Nystatin	Nystatin	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	suppressed
Mupirocin	Mupirocin	11	suppressed
Risperidone Er	Risperidone Microspheres	11	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error